Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 20/20 | 0.75 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.72 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.72 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.72 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL556139 | 0.92 | DPP4 (0.77) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL555713 | 0.90 | DPP4 (0.88) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL556575 | 0.89 | DPP4 (0.77) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL637434 | 0.88 | DPP4 (0.78) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL556156 | 0.88 | DPP4 (0.77) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL637919 | 0.88 | DPP4 (0.77) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| Trifluoroacetic Acid SCHEMBL2997087 | 0.88 | DPP4 (0.76) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL556897 | 0.87 | DPP4 (0.76) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL556490 | 0.87 | DPP4 (0.76) | DPP4CHRM1CHRM2CHRM3KCNH2 | |
| SCHEMBL637179 | 0.86 | DPP4 (0.81) | DPP4CHRM1CHRM2CHRM3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101293888-B | Xanthine derivative, production and use thereof as a medicament | BOEHRINGER INGELHEIM PHARMA | 2013-09-25 | — | — | CN | disclosed |
| US-20130165428-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-06-27 | — | — | US | disclosed |
| US-20100173916-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-08 | — | — | US | disclosed |
| CN-101293888-A | Xanthine derivative, production and use thereof as a medicament | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-10-29 | — | — | CN | disclosed |
| CN-100408579-C | Xanthine derivatives, process for their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-08-06 | — | — | CN | disclosed |
| CN-1492870-A | Xanthine derivatives, process for their preparation and their use as pharmaceutical compositions | ���ָ��Ӣ��ķ�������Ϲ�˾ | 2004-04-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130165428-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 334/4885CHRM2 599/4885 |
| US-20100173916-A1 | Xanthine Derivatives, the Preparation Thereof and Their Use as Pharmaceutical Compositions | DPP4, DPP3, DPP7 | DPP4 1/4885CHRM1 334/4885CHRM2 599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.